| 11804612 |
Hemrick-Luecke SK, Evans DC: Comparison of the potency of MDL 100,907 and SB 242084 in blocking the serotonin (5-HT)(2) receptor agonist-induced increases in rat serum corticosterone concentrations: evidence for 5-HT (2A) receptor mediation of the HPA axis. Neuropharmacology. 2002 Feb;42(2):162-9.
Direct-acting serotonin (5-HT) receptor agonists increase serum corticosterone in rats by activating receptors of the 5-HT (1A) or the 5-HT (2A/2C) subtypes. While involvement of 5-HT (1A) receptors in activation of the hypothalamic-pituitary-adrenocortical (HPA) axis is clear, the 5-HT (2) receptor subtype--5-HT (2A) or 5-HT (2C)--responsible for activation of the HPA axis by direct-acting 5-HT (2) receptor agonists has been difficult to determine due to the lack of selective pharmacologic agents. Recently, however, 5-HT (2) receptor antagonists with high selectivity for 5-HT (2A) and 5-HT (2C) receptor subtypes have been discovered. The selective 5-HT (2A) receptor antagonist MDL 100,907 and the selective 5-HT (2C) receptor antagonist SB 242084 were used to block the increases in rat serum corticosterone elicited by 5-HT (2) receptor agonists with varying degrees of affinity for 5-HT (2A) and 5-HT (2C) receptors. MDL 100,907 was fully effective in blocking the increases in corticosterone concentrations produced by quipazine, DOI, m-CPP and Ro 60-0175, whereas SB 242084 was ineffective or was only marginally effective. Our findings implicate 5-HT (2A) receptors rather than 5-HT (2C) receptors in mediating increases in rat serum corticosterone produced by direct-acting 5-HT (2) receptor agonists in vivo. |
4(0,0,0,4) |